Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289990 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,705
- Enrollment target
NCT01289990 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,705 participants.
The verdict
NCT01289990, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,705 participants
- Enrollment target
Study Summary
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
Interventions
- DRUG Placebo
- DRUG BI 10773
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,705 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01289990
The ClinicalTrials.gov registry entry for NCT01289990 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,705 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01289990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01289990 about?
NCT01289990 is a clinical study titled "Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes". This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
What is the current status of trial NCT01289990?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,705 participants. The study started on 2011-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01289990?
The interventions under investigation include: Placebo (DRUG), BI 10773 (DRUG).
Who is sponsoring clinical trial NCT01289990?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.